Postmenopausal osteopenia in hemodialysis patients
Conditions
Interventions
Transdermal low dose estrogen replacement therapy with cyclic administration of medroxyprogesterone acetate at 3-month interval
Oral administration of raloxifene every two days
No drug intervention
Sponsors
Department of Nephrology, Osaka University School of Medicine
Dai-Ni Rokushima Clinic Imai Naika Clinic Obi Clinic
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Postmenopausal hemodialysis patients with prevalent fracture or with a T-score of radial bone mineral density <-1.0 on the side without atrio-venous fistula.
Exclusion criteria
Exclusion criteria: 1. Patients with arteriosclerosis obliterans 2. Patients at high risk of venous thrombosis. i.e. bedridden patients 3. Patients with history of uterine cancer and/or breast cancer. 4. Patients receiving specific treatments other than active vitamin D that affect bone and mineral metabolism. i.e. calcitonin, bisphosphonate, and recombinant human PTH.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum calcium, phosphorus, parathyroid hormone, bone markers and lipid metabolism | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in bone mineral density at the radius on the side without atrio-venous fistula | — |
Countries
Japan
Contacts
Public ContactTakahito Ito
Osaka University School of Medicine Department of Nephrology
Outcome results
None listed